Credence Research, Inc. published the latest market report “Global mRNA Vaccine and Therapeutics Market: Growth, Future Prospects, and Competitive Analysis, 2015 – 2027”. The global mRNA Vaccine and Therapeutics market gained a market size of nearly USD 587.5 million in 2020 and is estimated to reach 2911.8 million in 2027 with a CAGR of 28.4 % during the forecast period.
Global mRNA Vaccine and Therapeutics Market, 2020 – 2027 (USD Million)
Browse the full report at https://www.credenceresearch.com/report/mrna-vaccine-and-therapeutics-market
mRNA vaccines are the advanced type of vaccine designed to generate immunity against infectious diseases. Many vaccines use inactivated or weakened form of the pathogen to trigger the immune response in the body. However, mRNA vaccines program cell to make a protein or even just a part of a protein which can induce an immune response against pathogens. With the advanced research many biological drug manufacturers are focusing on producing mRNA vaccines owing to their high efficiency.
Key Trends in Global Market
Increasing research on mRNA vaccines
mRNA vaccines are tested highly efficient for generating immune response in the human body. Also, the immunity generated by mRNA vaccines stays for long period of time. Owing to such advantages many bio-pharmaceutical companies are focusing on developing mRNA vaccines for deadly diseases. In addition, current COVID-19 pandemic also spurred the demand of mRNA vaccines and therapeutic. Many pharma majors such Pfizer-BioNTech and the Moderna have already developed mRNA vaccines for COVID-19, and many other market players are focusing to invest high amount for the development of mRNA-based vaccines
Global Market by Vaccine Type Insights
mRNA vaccine and therapeutic are primarily categorized as self-amplifying mRNA-based vaccines and conventional non-amplifying mRNA-based vaccines in this market. Owing to high efficiency of self-amplifying mRNA-based vaccines over other types of mRNA vaccines demand for self-amplifying mRNA vaccines is more. Which is also mainly causing the large share of the segment in overall market.
Global Market by Application Insights
Applications of mRNA vaccine and therapeutics are categorized as cancer, infectious disease, and other in the global market. infectious disease segment holds the largest share of the market owing to high prevalence of infectious disease worldwide. For instance, current COVID-19 pandemic has created huge demand for mRNA vaccine and therapeutic worldwide.
Global Market by Regional Insights
North America is the largest market for mRNA vaccine and therapeutics. The region expected to remain major revenue contributor for mRNA vaccine and therapeutics market over the forecast period. Presence of major bio-pharma players, and high investments on research for development of mRNA vaccines is primarily contributing to the major share of the market in this region.
Global Market Competitive Landscape
Some of the market players with a large share in the global market include Pfizer Inc., Arcturus Therapeutics Inc., Moderna Therapeutics Inc., BioNTech SE, CureVac AG, Etherna, ethris GmbH, Translate Bio Inc., GlaxoSmithKline PLC, Argos Therapeutics, Inc., Sangamo Therapeutics Inc. The report covers very detailed profiles of these key players.
Global mRNA Vaccine and Therapeutics Market by Vaccine Type, 2015 – 2027
· Self-amplifying mRNA-based Vaccines
· Conventional Non-Amplifying mRNA-Based Vaccines
Global mRNA Vaccine and Therapeutics Market by Application, 2015 – 2027
· Infectious Disease
Global mRNA Vaccine and Therapeutics Market by End User, 2015 – 2027
· Hospitals and Clinics
· Research Organizations
· Other End-User
Global mRNA Vaccine and Therapeutics Market by Region, 2015 – 2027
· North America
· Asia Pacific
· Latin America
· Middle East and Africa
Global mRNA Vaccine and Therapeutics Market: Key Players
· Pfizer Inc.
· Arcturus Therapeutics Inc.
· Moderna Therapeutics Inc.
· BioNTech SE
· CureVac AG
· ethris GmbH
· Translate Bio Inc.
· GlaxoSmithKline PLC
· Argos Therapeutics, Inc.
· Sangamo Therapeutics Inc.